Welcome to LookChem.com Sign In|Join Free
  • or
[2,5-dichloro-4-(1-methyl-3-indolylcarbonylamino)phenyl]acetic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

441715-25-9

Post Buying Request

441715-25-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

441715-25-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 441715-25-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,1,7,1 and 5 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 441715-25:
(8*4)+(7*4)+(6*1)+(5*7)+(4*1)+(3*5)+(2*2)+(1*5)=129
129 % 10 = 9
So 441715-25-9 is a valid CAS Registry Number.

441715-25-9Upstream product

441715-25-9Relevant academic research and scientific papers

Discovery of trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxamido) phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: An orally active, selective very late antigen-4 antagonist

Muro, Fumihito,Iimura, Shin,Sugimoto, Yuuichi,Yoneda, Yoshiyuki,Chiba, Jun,Watanabe, Toshiyuki,Setoguchi, Masaki,Iigou, Yutaka,Matsumoto, Keiko,Satoh, Atsushi,Takayama, Gensuke,Taira, Tomoe,Yokoyama, Mika,Takashi, Tohru,Nakayama, Atsushi,Machinaga, Nobuo

experimental part, p. 7974 - 7992 (2010/09/03)

We have focused on optimization of the inadequate pharmacokinetic profile of trans-4-substituted cyclohexanecarboxylic acid 5, which is commonly observed in many small molecule very late antigen-4 (VLA-4) antagonists. We modified the lipophilic moiety in 5 and found that reducing the polar surface area of this moiety results in improvement of the PK profile. Consequently, our efforts have led to the discovery of trans-4-[1-[[2,5-dichloro-4-(1-methyl-3- indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-( 2S)-pyrrolidinylmethoxy] cyclohexanecarboxylic acid (14e) with potent activity (IC50 = 5.4 nM) and significantly improved bioavailability in rats, dogs, and monkeys (100%, 91%, 68%), which demonstrated excellent oral efficacy in murine and guinea pig models of asthma. Based on its overall profile, compound 14e was progressed into clinical trails. In a single ascending-dose phase I clinical study, compound 14e exhibited favorable oral exposure as expected and had no serious adverse events.

PROCESS FOR PRODUCING PHENYLACETIC ACID DERIVATIVE

-

Page/Page column 34, (2010/11/23)

The present invention provides an advantageous process for producing an intermediate which is useful for producing a compound which exhibits excellent VLA-4 inhibitory effect and safety. Intermediates (III) and (XIII) are produced through conversion throu

METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE

-

Page/Page column 39-40, (2010/11/23)

The present invention provides an advantageous method for producing an intermediate which is useful for production of a compound which exhibits excellent VLA-4 inhibitory effect and safety. An intermediate (14) is produced through the following reaction s

PROCESS FOR PRODUCING PYRROLIDINE DERIVATIVE

-

Page/Page column 20, (2010/11/08)

This invention provides an industrially useful process for producing 1,4-transcyclohexanecarboxylic acid derivative (1) which has excellent VLA-4 inhibitory action and safety, and an intermediate which is useful in such method. More particularly, this inv

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 441715-25-9